ECE2014 Poster Presentations Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) (108 abstracts)
Comparison of the effectiveness of bromocriptine and cabergoline treatment of microprolactinomas in women based on results of dynamic pituitary gland MRI
Liudmila Kushnir & Zoya Zabarovskaya
Belorussian State Medical Institution, Minsk, Belarus.
Objective: The aim was to compare the effectiveness of the bromocriptine and cabergoline treatment of the women with microprolactinomas.
Materials and methods: 82 women with microprolactinomas were included in this study (51 patients received bromocriptine (Group 1) and 31 – cabergoline (Group 2)) with MRI-control after the first year of treatment (11 women from Group 1; 7 – from Group 2), the second (27 women from Group 1; 15 – from Group 2) and third year of treatment (13 women from Group 1; 9 – from Group 2). The drug dosage was titrated until the normalization of the serum prolactin level. The selective method of the statistical analysis was used. The changes were considered as positive if the size reduction of microprolactinomas was not <15%, negative – the enlargement was not <15%. Insignificant or absent changes were considered as no dynamics.
Results:
| MRI-dynamics | Group 1 1 year (n=11) | Group 2 1 year (n=7) | Group 1 2 year (n=27) | Group 2 2 year (n=15) | Group 1 3 year (n=13) | Group 2 3 year (n=9) | Group 1 (n=51) (%) | Group 2 (n=31) (%) |
| Positive | 2 | 4 | 9 | 8 | 1 | 4 | 12 (24%)* | 16 (52%)* |
| Negative | 2 | 0 | 1 | 0 | 3 | 1 | 6 (11%) | 1 (3%) |
| Without dynamics | 7 | 3 | 17 | 7 | 9 | 4 | 33 (65%) | 14 (45%) |
| MRI-dynamics | Group 1 1 year (n=11) | Group 2 1 year (n=7) | Group 1 2 year (n=27) | Group 2 2 year (n=15) | Group 1 3 year (n=13) | Group 2 3 year (n=9) | Group 1 (n=51) (%) | Group 2 (n=31) (%) |
| Positive | 2 | 4 | 9 | 8 | 1 | 4 | 12 (24%)* | 16 (52%)* |
| Negative | 2 | 0 | 1 | 0 | 3 | 1 | 6 (11%) | 1 (3%) |
| Without dynamics | 7 | 3 | 17 | 7 | 9 | 4 | 33 (65%) | 14 (45%) |
Conclusions: It was pointed out that the achievement of positive dynamics in women with microprolactinomas receiving treatment with dopamine agonists for 1–3 years was more than two times more frequently with cabergoline than bromocriptine. The findings suggest that cabergoline is preferable to bromocriptine in the treatment of the women with microprolactinomas.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more